NDAINJECTIONINJECTABLE
Approved
Feb 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM CITRATE GA 67 (gallium citrate ga-67) by Curium Pharma is clinical pharmacology gallium citrate ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. First approved in 1979.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Gallium Citrate Ga-67 is a radioactive diagnostic imaging agent that concentrates in viable tumors and focal infection sites through an unknown mechanism, binding to intracellular lysosomes. It is administered by intravenous injection and used for diagnostic staging and localization of malignancies and infections. The agent exhibits slow whole-body excretion with 65% retention at seven days post-injection.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; limited commercial team expansion expected as lifecycle matures.
Mechanism of Action
CLINICAL PHARMACOLOGY Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The mechanism of concentration is unknown, but investigational studies have shown that gallium Ga-67 accumulates in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Gallium Citrate Ga-67 offers stability in a diagnostic imaging niche but limited growth trajectory as the product approaches loss of exclusivity. Career development may focus on lifecycle management, cost optimization, and diagnostic market expertise rather than expansion or innovation.
Worked on GALLIUM CITRATE GA 67 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.